tradingkey.logo

Senseonics Holdings Inc

SENS
查看詳細走勢圖
7.430USD
+0.520+7.53%
收盤 02/06, 16:00美東報價延遲15分鐘
15.16M總市值
虧損本益比TTM

Senseonics Holdings Inc

7.430
+0.520+7.53%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+7.53%

5天

+1.36%

1月

+12.75%

6月

-19.75%

今年開始到現在

+34.60%

1年

-64.28%

查看詳細走勢圖

TradingKey Senseonics Holdings Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Senseonics Holdings Inc當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在醫療設備與耗材行業排名86/205位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為18.92。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Senseonics Holdings Inc評分

相關信息

行業排名
86 / 205
全市場排名
235 / 4521
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Senseonics Holdings Inc亮點

亮點風險
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.
業績高增長
公司營業收入穩步增長,連續3年增長37.12%
業績增長期
公司處於發展階段,最新年度總收入22.47M美元
估值高估
公司最新PE估值-0.31,處於3年歷史高位
機構減倉
最新機構持股6.48M股,環比減少20.35%
肯·費雪持倉
明星投資者肯·費雪持倉,最新持倉675.00股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.18

分析師目標

基於 8 分析師
買入
評級
18.917
目標均價
+214.23%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Senseonics Holdings Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Senseonics Holdings Inc簡介

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.
公司代碼SENS
公司Senseonics Holdings Inc
CEOGoodnow (Timothy T)
網址https://www.senseonics.com/
KeyAI